Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study Monica Niger , Federico Nichetti , Lorenzo Fornaro , Chiara Pircher , Federica Morano , Federica Palermo , Lorenza Rimassa , Tiziana Pressiani , Rossana Berardi , Andrea Casadei Gardini , Elisa Sperti , Lisa Salvatore , Davide Melisi , Francesca Bergamo , Salvatore Siena , Stefania Mosconi , Rafaella Longarini , Giuseppina Arcangeli , Salvatore Corallo , Laura Delliponti , Stefano Tamberi , Elena Fea , Giovanni Brandi , Ilario Giovanni Rapposelli , Massimiliano Salati , Paolo Baili , Rosalba Miceli , Silva Ljevar , Ilaria Cavallo , Elisa Sottotetti , Antonia Martinetti , Michele Droz Dit Busset , Carlo Sposito , Maria Di Bartolomeo , Filippo Pietrantonio , Filippo de Braud , Vincenzo Mazzaferro BMC Cancer（2024）
摘要
Biliary tract cancers (BTCs) are rare and lethal cancers, with a 5-year survival inferior to 20
更多 查看译文
关键词
Biliary tract cancers, Cholangiocarcinoma, Neoadjuvant chemotherapy, Cisplatin gemcitabine nabpaclitaxel
AI 理解论文
溯源树
样例
